About this trial
The primary objective of this exploratory study is to identify genes associated with acute rejection in liver transplant patients. To this end, a panel of acute rejection indicator genes (both humoral and cell-mediated) will be selected from results published in the literature and applied to biological material derived from biopsies. The secodnary objective is to identify genes associated with the diagnosis of humoral acute rejection and those associated with the diagnosis of cell-mediated acute rejection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with a diagnosis of post-OLT rejection prior to the visit at which they will be enrolled, with tissue available for RT-PCR investigations
Age ≥ 18 years
Informed consent
Disqualifiers
Age <18 years
Trial design
Single group
Treatments tested in this trial
Molecular diagnostic
Diagnostic testRNA will be analysed using a Real-Time PCR expression card (TaqMan Real-Time PCR assay technology - Thermo Fisher Scientific). The analysis will be performed using a Real-Time Light Cycler 480 (Roche). The expression card will be customised for the study, including the genes cxcl9/10, cav-1, rhoj, cdh5, cd96, tnfsf8, il-21r, vcam, klrk1
Treatment groups
Trial outcomes
Primary outcomes
Identification of genes associated with acute rejection liver transplant.
A panel of acute rejection indicator genes (both humoral and cell-mediated) will be selected from Scientific literature and applied to biological material from biopsies
Secondary outcomes
Identification of genes associated with the diagnosis of acute humoral rejection
A panel of acute rejection indicator genes applied to biological material from biopsies
Identification of genes associated with the diagnosis of acute cell-mediated rejection
A panel of acute rejection indicator genes applied to biological material from biopsies
Sponsors and contacts
Click on the lead sponsor to view all of their trials.